JNJJohnson & Johnson
Johnson & Johnson and its subsidiaries (the Company) have approximately 138,200 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. 10-K, Item 1
- Headquarters
- New Brunswick, NJ
- CEO
- Joaquin Duato
- Next results
- around Jan 20, 2027
Key numbers
Latest fiscal year, with ten years behind eachWhat changed
10-K filed Feb 11, 2026 against Feb 13, 2025| Area | What changed | Source |
|---|---|---|
| Risk factors | 6 new paragraphs, nothing like them in the previous 10-K | 10-K Item 1A |
| Cash from operations lower than net income | Cash from operations $24.5B vs net income $26.8B (FY ending 2025-12-28) | 10-K · XBRL |
| Accounting checks | 10 other checks clear, 1 worth a look | 10-K · XBRL |
| Insiders | No open-market buys in the last 90 days | Form 4 |
| Filings | 2 in the last 30 days | EDGAR |
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
What's new, in their words
10-K filed Feb 11, 2026Paragraphs in Risk Factors that were not in the 10-K filed 2025-02-13. Quoted as filed.
The planned separation of the Company's Orthopaedics business may not be completed on the terms or timeline currently contemplated, if at all, and may not achieve the expected results In October 2025, the Company announced its intention to separate the Company's Orthopaedics business. The Company is targeting completion of the planned…
10-K, Item 1A
Accounting checks
latest 10-K10 of 11 clear 1 worth a look. Checks, not verdicts.
- !Cash from operations lower than net incomeCash from operations $24.5B vs net income $26.8B (FY ending 2025-12-28)
- ✓Receivables +15.7% vs revenue +6.0% (+9.7 pts)
- ✓Inventory +14.0% vs revenue +6.0% (+8.0 pts)
- ✓Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
- ✓No statement of substantial doubt about going concern
- ✓No 8-K item 4.02 in the last 2 years
- ✓No NT 10-K or NT 10-Q in the last 2 years
- ✓The same matters as last year: U.S. Innovative Medicine Rebate Reserves - Managed Care, Medicare and Medicaid; Litigation Contingencies - Talc
- ✓No sentence in the 10-K concludes that controls were not effective because of a material weakness
- ✓No 8-K item 2.06 in the last 2 years
- ✓No 8-K item 1.03 in the last 2 years
In the last 30 days
All filings →- Oct 21, 202610-Q Quarterly report (10-Q) period ended Sep 27, 2026
- Oct 13, 20268-K Quarterly results 8-K item 2.02
About Johnson & Johnson
10-K, Feb 11, 2026Johnson & Johnson and its subsidiaries (the Company) have approximately 138,200 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. Johnson & Johnson is a holding company, with operating companies conducting business in virtually all countries of the world. The Company’s primary focus is products related to human health and well-being. Johnson & Johnson was incorporated in the State of New Jersey in 1887.
- Headquarters
- New Brunswick, NJ
- Country
- United States
- Reports in
- USD
- Listed on
- NYSE
- Fiscal year ends
- January 3
- Last results
- Oct 13, 2026
- Incorporated in
- NJ
Permanent link, kept if the ticker changes: /c/sec:0000200406 (SEC's CIK).
Work on JNJ in a spreadsheet:
Excel workbook (a sheet per section, ten years by column, charts, links to the filings) ·
CSV.
For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/JNJ/export.csv") into a cell.